Abstract
Activity of BCL-2 protein may be antagonised by BAX protein expression, thereby affecting cellular sensitivity to chemotherapeutic drugs. We analysed the BCL-2 protein expression of blast cells from 19 patients by flow cytometry and immunocytochemistry. This was compared to in vitro sensitivity to the anthracyclines and antimetabolites using the MTT assay. We found a significant correlation between BCL-2 expression and in vitro response to two antimetabolite drugs. One of 7 patients (14%) whose cells were sensitive to ara-C expressed BCL-2 compared to 4/4 patients (100%) whose cells were resistant to ara-C in vitro (p = 0.05). Furthermore, none of the three patients whose cells were sensitive to 6-TG expressed BCL-2 compared to 6/9 patients (67%) whose cells were resistant in vitro (p = 0.045). We found no other correlation between BCL-2 expression and any other chemotherapeutic drug analysed.
The ratio of BCL-2 to BAX may be more relevant clinically, therefore cells from a further 9 patients were analysed for both proteins. Whilst there was no overall relationship between BCL-2/BAX ratios and sensitivity to ara-C and 6TG, individual patients could be identified whose blast cells were resistant to ara-C and had high BCL-2/BAX ratios. Further analysis of the significance of these ratios to drug resistance may be of future prognostic value.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Green D, Martin S. The killer and the executioner: How apoptosis controls malignancy. Current Opinion in Immunology, 1995, 7, 694–703.
Reed JC. BCL-2 and the regulation of programmed cell death. J Cell Biol, 1994, 124, 1–6.
Reed JC. BCL-2: Prevention of apoptosis as a mechanism of drug resistance. Hematol/Oncol Clin, 1995, 9, 451–473.
Banker D, Groudine M. Measurement of spontaneous and therapeutic agent induced apoptosis with BCL-2 protein expression in acute myeloid leukaemia, Blood, 1997, 89, 243–255.
Brousset P, Benharroch D. Frequent expression of the cell death — inducing gene bax in Reed-Sternberg cells in Hodgkin’s Disease. Blood, 1996, 87, 2470–2478.
Pepper C, Bentley P. Regulation of clinical chemoresistance by BCL-2 and BAX oncoproteins in B-cell chronic lymphocytic leukaemia. Br J Haematol, 1996, 95, 513–517.
Pepper C, Hoy T. BCL-2/BAX ratios in chronic lymphoctic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer, 1997, 76, 935–938.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Balkham, S.E., Sargent, J.M., Elgie, A.W., Williamson, C.J., Taylor, C.G. (1999). Comparison of BCL-2 and Bax Protein Expression with in vitro Sensitivity to ARA-C and 6TG in AML. In: Kaspers, G.J.L., Pieters, R., Veerman, A.J.P. (eds) Drug Resistance in Leukemia and Lymphoma III. Advances in Experimental Medicine and Biology, vol 457. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4811-9_36
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4811-9_36
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7180-9
Online ISBN: 978-1-4615-4811-9
eBook Packages: Springer Book Archive